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Research
Methylmercury (MeHg) ranks among the
most highly bioconcentrated toxic metals in
the human food chain. It is typically bio-
magniﬁed in ﬁsh at the top of the food chain
up to 100,000 times the concentration in sur-
rounding waters, making fish consumption
the single major source of human MeHg
exposure [Agency for Toxic Substances and
Disease Registry (ATSDR) 1992; Counter
and Buchanan 2004; Gonzalez et al. 2005;
Horvat et al. 2003]. MeHg is also readily
absorbed by inhalation and dermal contact,
and it is able to cross the blood–brain and
blood–placental barriers, causing irreversible
damage to the brain. According to a National
Academy of Sciences report (NAS 2000),
60,000 fetuses are at risk of MeHg-induced
brain damage in the United States, to such a
degree that it may affect the children’s school
performance.
In contrast to the rarity of clinical MeHg
toxicity, many people are exposed to MeHg
levels that, while generally considered to be
quite low, may produce subtle neurologic
effects, particularly in infants and children
(Chapman and Chan 2000; Clarkson 1998;
Counter and Buchanan 2004). MeHg toxicity
exhibits a latent period after exposure such that
by the time clinical signs and symptoms have
appeared, it is usually too late to reverse the
damage (Clarkson 1997). To assess MeHg
exposure and/or toxicity, several biomarkers
have been proposed (Ali et al. 1992; Diaz et al.
2004; Iyengar and Rapp 2001; Thompson
et al. 1999). The sampling techniques for
many of these biomarkers are invasive and
therefore unrealistic for use in humans for pre-
ventive intervention. Hair remains the current
medium of choice for assessing MeHg expo-
sure in humans (Clarkson 1998). The total or
segmental hair level of MeHg provides an
excellent measure of exposure history over a
recent defined past, which may span several
months, because the growth rate of hair is
about 1 cm/month. However, hair analysis is
not useful for acute exposures or for the assess-
ment of current body burden (Boischio and
Cernichiari 1998; Boischio et al. 2000; Cox
et al. 1995). Furthermore, the new U.S.
Environmental Protection Agency (EPA) refer-
ence level of only 1–2 ppm (Rice et al. 2000) is
also close to the background level found in
hair. These new U.S. EPA guidelines also
increase the number of people that are consid-
ered at risk of MeHg poisoning, and thus they
increase the number of people that need to be
monitored both in epidemiologic studies and
in the general population.
Several chelating agents have been studied
as potential MeHg antidotes and more recently
as a provocative mercury “challenge” for the
purpose of biomonitoring (Aposhian et al.
1995; Domingo 1995; Frumkin et al. 2001;
Risher and Amler 2005). Unfortunately, all
chelating agents identiﬁed so far have signiﬁ-
cant side effects and are also known to differ in
their efficacy for various forms of mercury,
route of administration, and route of excretion
(Risher and Amler 2005). The current choices
and the most widely used MeHg chelators are
the thiol-containing compounds meso-2,3-
dimercaptosuccinic acid (DMSA, succimer,
captomer, chemet) and 2,3-dimercapto-1-
propanesulfonate (DMPS, dimaval, unithiol)
(Risher and Amler 2005). However, DMSA
and DMPS have limited stability in solution,
limited availability for human use, and a
propensity to mobilize other minerals (espe-
cially divalent cations) essential for normal
physiologic functions (Grandjean et al. 1997;
Mann and Travers 1991; Nogueira et al. 2003;
Risher and Amler 2005). N-Acetylcysteine
(NAC) has also been shown to be remarkably
effective at enhancing MeHg excretion in mice
(Ballatori et al. 1998). Mice that received
NAC in the drinking water (10 mg/mL) start-
ing 48 hr after MeHg administration excreted
47–54% of the mercury in urine over the sub-
sequent 48 hr, compared with only 4–10% in
control animals (Ballatori et al. 1998). NAC is
a relatively simple, nontoxic N-acetyl derivative
of cysteine, which contains a thiol group that is
stabilized by acetylation of the amino group.
Unlike other chelating agents, NAC is a potent
antioxidant/detoxicant and does not alter tis-
sue distribution of essential metals (Hjortso
et al. 1990). NAC was previously shown to be
protective against MeHg-induced embryo-
toxicity (Ornaghi et al. 1993), although the
mechanism was not identified. Thus, these
ﬁndings open the possibility that NAC may be
used to accelerate MeHg excretion and thus
minimize its toxicity.
In the present study we tested the hypoth-
esis that a standardized dose of NAC will pro-
duce a transient increase in urinary MeHg
excretion that is proportional to the body bur-
den of MeHg using a rodent model. We also
examined whether NAC is effective at acceler-
ating urinary excretion of MeHg in rats of
both sexes and at different ages, and whether
it can diminish MeHg levels in the developing
embryo. Because the toxic effects of MeHg
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BACKGROUND: Many people, by means of consumption of seafood or other anthropogenic sources,
are exposed to levels of methylmercury (MeHg) that are generally considered to be quite low, but
that may nevertheless produce irreversible brain damage, particularly in unborn babies. The only
way to prevent or ameliorate MeHg toxicity is to enhance its elimination from the body.
OBJECTIVES: Using N-acetylcysteine (NAC), we aimed to devise a monitoring protocol for early
detection of acute exposure or relatively low MeHg levels in a rodent model, and to test whether
NAC reduces MeHg levels in the developing embryo.
RESULTS: NAC produced a transient, dose-dependent acceleration of urinary MeHg excretion in
rats of both sexes. Approximately 5% of various MeHg doses was excreted in urine 2 hr after injec-
tion of 1 mmol/kg NAC. In pregnant rats, NAC markedly reduced the body burden of MeHg, par-
ticularly in target tissues such as brain, placenta, and fetus. In contrast, NAC had no signiﬁcant
effect on urinary MeHg excretion in preweanling rats.
CONCLUSIONS: Because NAC causes a transient increase in urinary excretion of MeHg that is pro-
portional to the body burden, it is promising as a biomonitoring agent for MeHg in adult animals.
In view of this and because NAC is effective at enhancing MeHg excretion when given either orally
or intravenously, can decrease brain and fetal levels of MeHg, has minimal side effects, and is
widely available in clinical settings, NAC should be evaluated as a potential antidote and biomoni-
toring agent in humans.
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http://dx.doi.org/ [Online 17 October 2007]often do not manifest themselves for several
days or even weeks after exposure and because
the effects are largely irreversible once they
appear (Clarkson 1997), early detection of
exposure and prompt therapeutic intervention
with a complexing agent, such as NAC, is
critical for preventing or minimizing toxicity.
Materials and Methods
Animals and reagents. Wistar rats were
obtained from Charles River Laboratories
(Kingston, NY). They were allowed an
acclimatization period of at least 5 days in a
temperature- and humidity-controlled room
with a 12-hr alternating light cycle, and were
maintained on standard laboratory chow with
water ad libitum. Animals were used for exper-
iments at 250–300 g body weight and with
four animals per group, except where other-
wise stated. All experiments were conducted in
accordance with the guidelines of the National
Institute of Health for care of laboratory ani-
mals [Office of Laboratory Animal Welfare
(OLAW) 2002]. We obtained [14C]MeHg
from American Radiolabeled Chemical, Inc.
(St. Louis, MO), NAC from Sigma Chemical
Co. (St. Louis, MO), and other chemicals and
reagents from J.T. Baker (Philipsburg, NJ)
and VWR (West Chester, PA).
Surgical procedure and urine collection
from anesthetized rats. The animals were
treated humanely and with regard for allevia-
tion of suffering. Rats were anesthetized by
intraperitoneal administration of pentobarbital
sodium (55–60 mg/kg). The right jugular vein
was exposed, a nick was made in the vein, and a
PE-50 tube (Becton Dickinson & Co., Sparks,
MD) was inserted into the vein and tied in
place by a ligature at the distal end of the vein.
The PE-50 tube was ﬁlled with glucose solution
(140 mM) via a 22-gauge needle connected to a
20 mL syringe using a syringe pump (model
341B; Sage Instruments, Boston, MA); an infu-
sion rate of 4.1 mL/hr was applied throughout
the experiments. The trachea was cannulated
using a PE-205 tube to allow easy passage of
air. A rectal probe and heating lamp connected
to a Tele-Thermometer (Yellow Springs
Instrument, Yellow Springs, OH) were used
to monitor and maintain the rat’s body tem-
perature at 37°C. Following laparotomy, the
urinary bladder was cannulated using the ﬂared
end of a PE-50 tube that was tied in place.
Excreted urine was collected at 30-min inter-
vals into tared 12 × 75 mm test tubes through-
out the experiment. [14C]MeHg (0.1 µmol/kg,
except when otherwise stated) was given intra-
venously (iv) at a rate of 200 µL/min after the
collection of the ﬁrst urine sample. Two hours
after the injection of [14C]MeHg, a bolus dose
of NAC (1.0 mmol/kg, except when otherwise
stated) was given iv at a rate of 200 µL/min. In
another experiment, a second NAC dose was
given 1 hr after the ﬁrst dose. The experiment
was terminated 2.5 hr after NAC injection. At
the end of the experiments, we collected
1.0 mL blood by cardiac puncture and then
removed and weighed the liver, kidney,
spleen, and brain.
MeHg disposition in pregnant rats. Rats
were placed individually in stainless-steel meta-
bolic cages (Lab Products Inc., Rochelle Park,
NJ) and were allowed to acclimate to the cages
for 3 days. On gestation day (GD) 14, rats
were injected iv via lateral tail vein with
[14C]MeHg (2 mL/kg of 0.1 µmol MeHg/kg
with 5 µCi 14C/kg); after 24 hr, some rats were
supplied drinking water containing 10 mg/mL
NAC ad libitum for 2 days, while others
served as controls. Fresh NAC solution was
prepared daily. At the end of the experiments,
the uterus was removed and two fetoplacental
units were selected from each animal. The
fetus and placenta were separated, and other
maternal tissues were removed and weighed.
Determination of [14C]MeHg content.
Aliquots of 100 µL were taken from all urine
samples (on exceptional cases, < 100 µL but
at least 50 µL of urine was used). Opti-Fluor
(5 mL; Packard Instrument Co., Meriden,
CT) was added to urine aliquots in scintilla-
tion vials, and the mixture was vortexed and
allowed to stand in the dark overnight before
counting on a Beckman 6500 scintillation
spectrometer (Beckman Coulter, Inc.,
Fullerton, CA). A small cross section (~ 0.2 g)
cut from each tissue or 1.0 mL blood was put
into a tared 20-mL glass vial and stored at
–20°C for not more than 1 week before fur-
ther treatment. To minimize blood content in
the tissue samples, the tissues were blotted on
absorbent paper. In the case of the brain, we
carefully removed the meninges, along with
small blood clots, under a light microscope.
To solubilize the tissues, we added 1.0 mL
Solvable (Packard Instrument Co.) per 0.1 g
tissue or 0.5 mL blood; the glass vial was
heated in a shaking incubator at 60°C and a
speed of 150 rpm for 2–3 hr, which allowed
complete solubilization of the tissues. The
samples were allowed to cool to room temper-
ature; 0.2 mL 30% H2O2/mL of solution was
added to the samples in 0.1 mL aliquots, with
tubes swirled between additions. For blood
samples, 0.1-mL of 0.1 M EDTA/mL of
Solvable was added before 0.3 mL 30%
H2O2/mL of Solvable. After standing at room
temperature for 15–30 min, the vials were
capped tightly and then heated for another
1 hr in a shaking incubator at 60°C and a
speed of 200 rpm. The Solvable, EDTA,
and/or H2O2 alone (at the proportions added
to the tissues) were put in another vial and
taken through all the heating procedure to
correct for background counts. Scintillation
ﬂuid (5 mL) was added to 200 µL aliquots of
the solubilized tissues, vortexed, and allowed
to stand in the dark overnight before count-
ing. For calculating the percent of the dose in
the blood, we used a blood volume of 6% of
body weight.
Results
Dose-dependent stimulation of urinary MeHg
excretion by increasing doses of NAC. In agree-
ment with recent ﬁndings from our laboratory
(Madejczyk et al. 2007), NAC produced a
rapid, transient increase in urinary MeHg
excretion in rats that had received 0.1 µmol/kg
[14C]MeHg 2 hr prior to NAC administration
(Figure 1). Approximately 5% of the MeHg
dose was excreted during the 2 hr after NAC
administration in both male and female rats,
whereas control animals excreted < 0.1% of
the dose over the same time interval (data not
shown). Animals that received double doses of
NAC had two peaks of excretion, and there
were minimal differences between the sexes
(Figure 1B). The total percentage excreted in
the 2 hr after NAC injection was not different
between sexes when a single dose was given,
but this became signiﬁcant when two doses of
NAC were given within the same time period,
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Figure 1. Effect of NAC on urinary MeHg excretion in male and female rats. Animals received [14C]MeHg (0.1 µmol/kg body weight) at time zero and NAC
(1 mmol/kg body weight) after 2 hr (A,B); some animals (B) received a second dose of NAC 1 hr later. (C) Residual levels of [14C]MeHg in selected organs at the
end of experiments. Values are mean ± SD; n = 4 rats per group.
*Signiﬁcantly different from control (p < 0.05).
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with the male group being slightly higher
(Figure 1B). MeHg distributes within tissue
compartments at a very rapid rate compared
with its rate of excretion, and its elimination
follows first-order kinetics (Clarkson 1993).
Because MeHg was given iv in these studies,
MeHg concentrations in most tissues
approached steady-state levels within about
1 hr, and were not subject to ﬂuctuations due
to normal excretion at this short time interval.
Being a single compartment distribution, the
blood levels of MeHg reﬂect levels in different
tissues at constant ratios.
We compared the residual MeHg in
selected tissues of the male group that received
double doses of NAC with control animals
without NAC treatment (Figure 1C). Similar
results were obtained for female rats (data not
shown). The MeHg was undetectable in the
brain of both treated and untreated animals
within the short time frame of this experiment;
however, the blood levels of MeHg in NAC-
treated animals were lower than those in the
untreated group (Figure 1C). We observed no
differences in the residual MeHg in the liver,
kidney, and spleen of the two groups.
To determine whether the effects of NAC
are dose dependent, we treated animals with
MeHg at 0.1 µmol/kg and then with different
doses of NAC (0.125–1.5 mmol/kg). Control
animals excreted only minimal amounts of
MeHg in urine (< 0.1% in 2 hr following
vehicle injection), but this was markedly
enhanced by increasing doses of NAC
(Figure 2 A,B). At the lowest NAC dose
(0.125 mmol/kg), urinary MeHg excretion
was double that of controls during the 2 hr
after NAC administration (Figure 2A). At the
highest NAC dose tested (1.5 mmol/kg),
about 10% of the MeHg dose was excreted in
urine in 2 hr (Figure 2B). When the correla-
tion between NAC dose and urinary MeHg
excretion was plotted, we observed a nearly
linear relationship (Figure 2C).
A standard dose of NAC stimulates uri-
nary excretion of MeHg with a relatively con-
stant predictive ratio. To test the hypothesis
that a standardized dose of NAC will produce
an increase in urinary MeHg excretion that is
proportional to the body burden of MeHg, we
treated animals with different doses of MeHg
(0.01–1.0 µmol/kg), but all groups received a
standard dose of 1.0 mmol/kg NAC at 2 hr
after MeHg administration. The injection of
NAC was followed by a sharp increase in uri-
nary MeHg excretion at all MeHg doses
(Figure 3A). Except for the lowest MeHg
dose, the percentage excreted in the 2 hr fol-
lowing NAC injection was relatively constant,
with a mean ± SD of 5.2 ± 0.3% of dose
excreted over this time period (Figure 3B).
When the amount of MeHg excreted in urine
was plotted against the MeHg dose, we
observed a linear relation (Figure 3C).
NAC in drinking water lowers the body
burden and accelerates the urinary excretion
of MeHg in pregnant rats. Because fetuses are
exposed to MeHg via maternal blood and
hence are prone to the danger of develop-
mental abnormalities (Ornaghi et al. 1993),
we determined the effectiveness of NAC in
reducing the body burden of MeHg in preg-
nant dams. Pregnant dams were injected with
MeHg via the lateral tail vein on GD14;
24 hr later some animals were supplied drink-
ing water containing 10 mg/mL of NAC
ad libitum for another 48 hr. Animals were
then anesthetized, and we removed from each
dam two fetoplacental units along with blood,
liver, kidney, spleen, and brain for MeHg
determination. The residual MeHg was sig-
nificantly lower in the tissues isolated from
the dams exposed to NAC in drinking water
than in tissues from untreated dams, includ-
ing the placenta and fetus (Figure 4A,B).
NAC had different effects on individual tissue
MeHg levels: blood and liver levels were
decreased by approximately 60–80%, whereas
kidney MeHg decreased by only 20%. In
contrast, MeHg levels in the fetus and in pla-
centa and maternal brain were decreased by
approximately 70–90%.
NAC fails to stimulate urinary MeHg
excretion in preweanling rats. Infants whose
brains are still developing are at higher risk of
MeHg poisoning (Clarkson 2002). Thus, it is
important to determine whether NAC is effec-
tive in stimulating urinary excretion of MeHg
in young animals. To test this possibility, we
treated rats between 15–19 days of age with
0.1 µmol/kg MeHg iv, followed by a single
dose of NAC 1 hr after MeHg injection.
However, NAC administration had only min-
imal effects on urinary excretion of MeHg in
the preweanling animals (Figure 5).
Discussion
Previous studies from our laboratory have sug-
gested that NAC may be an ideal agent for
enhancing MeHg excretion in exposed indi-
viduals because of its ability to markedly
stimulate MeHg excretion when given orally,
its relatively low toxicity, and its wide avail-
ability in the clinical setting (Ballatori et al.
Figure 2. Dose-dependent effects of NAC on urinary MeHg excretion in male rats that received [14C]MeHg (0.1 µmol/kg body weight). Two hours after [14C]MeHg
administration, animals received vehicle or different doses of NAC [vehicle or 0.125 mmol/kg NAC (A); 0.25–1.5 mmol/kg NAC (B)]. (C) Total amounts of [14C]MeHg
excreted in urine during the 2 hr after NAC injection plotted against the various doses of NAC. Values are mean ± SD; n = 4–5 rats per group.
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0.25 0.5 0.2 0.6 0.8 11998). The present study provides strong sup-
port for this hypothesis. The efﬁcacy of NAC
was demonstrated in rats of both sexes, and in
a dose-dependent manner. Moreover, NAC
was capable of reducing MeHg levels in the
fetus, indicating that NAC may be protective
against MeHg embryotoxicity. In contrast,
NAC was ineffective when administered iv to
preweanling rats; this suggests that the trans-
port mechanisms responsible for NAC stimu-
lation of MeHg excretion are not yet mature
in these animals. In addition, our results
demonstrate that the amount of MeHg
excreted into urine after NAC challenge is
proportional to the MeHg body burden, indi-
cating that NAC may be useful as a bio-
monitoring agent.
The increase in urinary MeHg excretion
was directly dependent on the dose of NAC.
By administering 1 mmol NAC/kg to male
and female rats exposed to 0.1 µmol MeHg,
about 5% of the body burden was excreted in
urine in < 2 hr; this effect doubled within the
same time period when two doses of NAC
were applied at 1-hr intervals. At double doses
of NAC, differences in the percentage of
excreted MeHg between the sexes became
apparent, being somewhat higher in male than
in female rats (Figure 1B). Although the rea-
son for this difference is unknown, it may be
related to differences in the expression of
transporters that are thought to be involved in
the transport of the MeHg–NAC complex, or
of NAC itself, across the renal tubular cells
(Madejczyk et al. 2007). Sex is known to
inﬂuence pharmacokinetic parameters such as
clearance and half-life of many drugs (Buist
et al. 2002). For example, the expression of
the basolateral membrane organic anion trans-
porter-1 (Oat1), which has been implicated in
the transport of MeHg–NAC complex (Koh
et al. 2002), is greater in male rats than in
females (Buist et al. 2002).
In the present study we also found a dra-
matic reduction in body burden of MeHg
when NAC was administered to pregnant rats
via the drinking water (Figure 4A). Also, the
placental and fetal MeHg levels of the pregnant
rats were significantly reduced (Figure 4B).
These observations further suggest that NAC
may be an excellent agent for enhancing
MeHg elimination in exposed individuals.
Blood and liver levels of MeHg were decreased
by 60–85%, and comparable decreases were
seen in crucial tissues such as the brain (from
0.3% of the dose to 0.03%; 90% decrease),
placenta (from 0.1% to 0.01%; 90% decrease),
and fetus (0.08% to 0.02%; 75% decrease).
Thus, in addition to being an antioxidant,
which has been attributed to its protective role
against MeHg embryotoxicity (Ornaghi et al.
1993), the present study demonstrates that
NAC actually lowered MeHg levels in fetuses
and placenta. 
Our ﬁndings therefore indicate that NAC
may be very useful in the therapeutic manage-
ment of pregnant women whose babies are in
danger of prenatal MeHg poisoning. Mass
health disasters in Minamata and Niigata,
Japan, and in Iraq have conﬁrmed that MeHg
is neurotoxic and that the prenatal period is the
most sensitive stage of the life cycle (Davidson
et al. 1998). Thus, even though controversies
may surround the maternal levels of MeHg that
predispose to future neurologic problems in
children (Davidson et al. 1998; Grandjean et al.
1997), it is prudent to decrease MeHg levels,
even in asymptomatic women living in areas
with a history of dependence on seafoods that
are highly contaminated with MeHg. Because
the NAC doses used in the present study are
comparable with those used in humans who
have overdosed on acetaminophen (i.e.,
140 mg/kg or 0.86 mmol/kg) (Smilkstein et al.
1991; Woo et al. 2000), we speculate that a
similar NAC dosing regimen as used in aceta-
minophen overdoses would likely be safe and
effective in accelerating MeHg excretion in
humans. Limited data based mainly on case
reports of treatment of acetaminophen over-
dose in pregnancy suggest that NAC may also
be safely administered during pregnancy
(Wilkes et al. 2005). Thus, NAC may be a
safe therapeutic agent in pregnant women to
decrease the levels of this toxic agent in devel-
oping embryos. 
Interestingly, NAC failed to signiﬁcantly
increase the urinary excretion of MeHg in pre-
weanling rats (postnatal days 15–19; Figure 5).
This may not be surprising because age is
known to inﬂuence pharmacokinetic parame-
ters, including the extent of and sensitivity to
drug effects (Fanos and Dall’Agnola 1999;
Tune 1975). Moreover, the expression levels of
transporters that are thought to be involved in
the transport of the MeHg–NAC complex
across the renal tubule cells are immature in
preweanling rats. In particular, expression of
Oat1 in rat kidney is low at birth, but it
approaches adult levels at around 30 days of
age (Buist et al. 2002). Oat3 in the kidney of
developing rats is expressed as early as postnatal
day 10 (Buist et al. 2002); however, Oat3 does
not seem to participate in the transport of the
MeHg–NAC complex (Koh et al. 2002).
Likewise, the expression of the apical mem-
brane organic anion transporter Mrp2 (multi-
drug resistance-associated protein-2), which is
thought to participate in the tubular transport
of MeHg–NAC (Madejczyk et al. 2007), is
also low in the preweanling animal (Maher
et al. 2005; Tomer et al. 2003) and may con-
tribute to the inability of NAC to increase
MeHg excretion in young animals. Thus, the
present findings support the involvement of
Oat1 and Mrp2 in the urinary excretion of the
MeHg–NAC complex (Koh et al. 2002;
Madejczyk et al. 2007) and conform to the
reports on developmental expression of trans-
porters (Buist et al. 2002). In contrast, our
results also indicate that NAC may not be use-
ful as a complexing agent in one age group that
is relatively vulnerable to the neurotoxic effect
of MeHg—neonatal animals.
Figure 6 illustrates a model that may
explain the effects of NAC on urinary MeHg
excretion. After oral NAC administration,
NAC is rapidly absorbed from the gastro-
intestinal tract, and blood NAC levels rise
Methylmercury antidote and biomonitoring agent 
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Figure 4. Effect of NAC on body burden and transplacental transfer of MeHg in pregnant rats. Residual
levels of [14C]MeHg in selected organs (A) and in placentas and fetuses (B) from pregnant rats that
received [14C]MeHg (0.1 µmol/kg) via lateral vein on GD14. After 24 hr, NAC-treated rats received 10 mg/mL
NAC in their drinking water for 2 days. Values are mean ± SD; n = 4 rats in each group or 8 fetoplacental
units from 4 rats in each group. 
*Signiﬁcantly different from control (p < 0.05).
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Figure 5. Effects of NAC on urinary MeHg excretion
in preweanling and adult rats treated with
0.1 µmol/kg [14C]MeHg 1 hr before treatment with
1 mmol/kg NAC. Values shown are amounts of
[14C]MeHg excreted in urine 2 hr after NAC injection
(mean ± SD); n = 4–5 rats per group. 
*Signiﬁcantly different from adult animals (p < 0.05).
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*quickly (Borgstrom et al. 1986; Rodenstein
et al. 1978). NAC can spontaneously (i.e.,
nonenzymatically) form a thermodynamically
stable mercaptide complex with MeHg to form
MeHg–NAC. MeHg–NAC is an excellent
substrate for Oat1 (Koh et al. 2002), a major
renal basolateral membrane organic anion car-
rier, and thus MeHg–NAC can be transported
from blood into the renal tubular cell via this
carrier. It is important to note that NAC itself
is also efficiently cleared by the kidney and
excreted into urine in high concentrations
(Borgstrom et al. 1986; Rodenstein et al.
1978). In humans the half-life of NAC in
blood plasma is only 2 hr; this short half-life is
due largely to NAC’s rapid urinary excretion
(Borgstrom et al. 1986; Rodenstein et al.
1978). Approximately one-third of the NAC is
excreted in urine during the first 12 hr after
administration (Borgstrom et al. 1986); this
half-life for NAC in blood is also consistent
with the rapid acceleration of MeHg excretion
observed during NAC administration, and
with the rapid deceleration in MeHg excretion
after NAC withdrawal (Figures 1–3).
Once the MeHg–NAC complex enters
the renal tubular cell, MeHg may exchange
with other thiols, including reduced gluta-
thione (GSH), to form MeHg–SG (Figure 6),
although a signiﬁcant fraction likely remains as
MeHg–NAC, given the high amount of NAC
present under these conditions. Both the NAC
and GSH complexes are substrates for the api-
cally located, ATP-driven Mrp2 transport pro-
tein (Ballatori 2002; Madejczyk et al. 2007),
thus providing an efficient mechanism for
excretion of MeHg into renal tubular ﬂuid for
eventual excretion in urine (Figure 6).
Findings of the present study also demon-
strate that NAC offers biomonitoring potential
for exposure to MeHg. The results from rats
exposed to a wide range of MeHg doses
showed that NAC at an iv dose of 1 mmol/kg
body weight produced a urinary excretion
equivalent to about 5% of the body burden in
< 2 hr (Figure 3B). Although the latter dose–
response studies with NAC were performed
using iv administration, the observation that
NAC in drinking water (oral dosing) resulted
in the excretion of about 4% of the dose in the
ﬁrst 24 hr (Madejczyk et al. 2007) and the fact
that NAC is highly effective at enhancing uri-
nary MeHg excretion when given either orally
or iv (Ballatori et al. 1998; Madejczyk et al.
2007) make it highly likely that it will also be
an effective biomonitoring agent when given
orally. However, additional studies are needed
to test this hypothesis and to examine whether
NAC is also effective in humans exposed to
MeHg. Nevertheless, the ﬁndings that NAC is
both relatively selective for MeHg and quick-
acting are remarkable, and also suggest that an
oral NAC challenge test may be useful for
monitoring MeHg body burden. As noted pre-
viously (Boischio and Cernichiari 1998;
Boischio et al. 2000; Cox et al. 1995),
although hair is an excellent biomarker of
MeHg exposure, hair growth rate is only about
1 cm/month. Therefore, the hair level of
MeHg may not provide an early warning
before the onset of neurologic effects after an
acute exposure to MeHg. A safe chelation chal-
lenge is thus a preferable choice for preventive
purposes because it reflects the status of the
body burden at a particular point in time.
Thus, if a person has an elevated body burden
of MeHg, the administration of NAC is
expected to cause a short-term increase in its
urinary excretion (Frumkin et al. 2001).
Because MeHg is less toxic to the kidney
compared with inorganic mercury (Aleo et al.
2005; Lash et al. 2005), the rapid elimination
of MeHg via urine after NAC administration
should be a safe therapeutic and diagnostic
option. Rapid urinary excretion also ensures
that MeHg is quickly eliminated before it is
significantly demethylated to inorganic 
mercury, a form that is more nephrotoxic.
Moreover, in contrast to other complexing
agents (Aposhian et al. 1995; Cantilena and
Klaassen 1982), NAC does not alter tissue dis-
tribution of essential metals (Hjortso et al.
1990). Because of its nucleophilic properties,
NAC is also able to inactivate electrophiles and
free radicals directly through conjugation and
reduction (Moldeus et al. 1986). More impor-
tantly, ﬁndings of the present study show that
NAC is effective at enhancing MeHg excretion
when given either orally or iv. In addition,
NAC is a powerful antioxidant and is widely
available in clinical settings, where it is being
used both orally and iv at a dose of 140 mg/kg
for treating acetaminophen (paracetamol) toxi-
city (Smilkstein et al. 1991; Woo et al. 2000);
this dose of NAC is comparable to the dose we
used in the present study. Thus, NAC may be
effective at enhancing MeHg excretion in
exposed individuals, and it should be evaluated
for both biomonitoring purposes and for
decreasing the MeHg body burden in humans.
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